Who was studied?
A 57-year-old woman with stage IVB cervical squamous cell carcinoma, HER2 IHC 2+, kidney injury and severe anemia.
What does the publication report?
The best response was partial response after a regimen including radiation, adebrelimab, disitamab vedotin and cytokines. PFS exceeded 8 months at last follow-up.
Safety findings
A grade 3 rash attributed to IL-2 resolved after withdrawal and supportive care.
How should we interpret it?
A single participant within the registered trial, not an independent trial or proof of suitability for all patients with kidney dysfunction.
Read the original source
This independently written summary was checked against the publicly available abstract. Selected figures, where included, are checked against the full publication. This is not a full-paper translation or a clinical recommendation.
Case Report: PRaG 3.0 therapy for advanced cervical cancer with severe comorbidities · DOI: 10.3389/fonc.2026.1912098
Related publications from the same research program
- Evaluation of RC48-ADC in Combination with PRaG Regimen: An Open-Label, Prospective, Multicentre Study Assessing Efficacy and Safety for Advanced Refractory HER2-Expressing Solid Tumors (PRaG3.0 Study Protocol)
- A multicenter, phase II trial of RC48-ADC combined with radiotherapy, PD-1/PD-L1 inhibitor, GM-CSF, and sequential IL-2 (PRaG3.0 regimen) for salvage therapy in patients with HER2-expressing advanced solid tumors.
- An open-label, multicenter, phase II study of RC48-ADC combined with radiotherapy, PD-1/PD-L1 inhibitor sequential GM-CSF and IL-2 for salvage therapy in patients with HER2-expressing advanced solid tumors(PRaG3.0).
Educational reporting, not individualized medical advice. Discuss treatment decisions with your clinical team.